Vinorelbine in cancer therapy

Current Drug Targets

Volumn 13, Issue 8, 2012, Pages 1065-1071

  Capasso, Anna ^a  

^a UNIVERSITY OF SALERNO   (Italy)

Author keywords

Antimitotic; Cancer; Vinorelbine

Indexed keywords

2C3 ANTIBODY; ABJ 879; COLCHICINE; CRYPTOPHYCIN DERIVATIVE; CYCLIN A; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; DOCETAXEL; EPOTHILONE B; EPOTHILONE D; ERIBULIN; HALICHONDRIN B; HISTONE H3; IXABEPILONE; LAULIMALIDE; NAVELBINE; PACLITAXEL; PACLITAXEL POLIGLUMEX; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VINBLASTINE; VINFLUNINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CELL CYCLE; CELL CYCLE ARREST; CELL INTERACTION; CELL INVASION; CELL PROLIFERATION; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL CYCLE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASMS; VINBLASTINE;

EID: 84863540978     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012802009017     Document Type: Article

References (43)

1. Hirsch J. An anniversary for cancer chemotherapy. JAMA 2006; 296 (12): 1518-18120
2. Joensuu H. Systemic chemotherapy for cancer: from weapon to treatment. Lancet Oncol 2008; 9 (3): 304.
3. Skeel RT. Handbook of Cancer Chemotherapy. Lippincott Williams & Wilkins 2003.
4. De Souza CP, Osmani SA. Mitosis, not just open or closed. Eukaryotic Cell 2007; 6 (9): 1521-1527.
5. Maton A, Hopkins, JJ, Susan LHD, Quon W, David W, Jill D. Cells: Building Blocks of Life. New Jersey: Prentice Hall 1997; pp: 70-4.
6. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Mitosis. Molecular Biology of the Cell. Garland Science 2002.
7. Freeman S. Cell Division. pp. 155-174.
8. Lodish H, Berk A, Zipursky L, Matsudaira P, Baltimore D, Darnell J. Overview of the Cell Cycle and Its Control. Molecular Cell Biology, 4th ed. W.H. Freeman 2000.
9. McKnight J. Principles of chemotherapy. Clin Tech Small Anim Pract 2003; 18 (2): 67-72
10. Chabner B, Longo DL. Cancer Chemotherapy and Biotherapy: Principles and Practice. Philadelphia. Lippincott Willians & Wilkins 2006.
11. Jordan MA, Thrower D, Wilson L. Mechanism of cell proliferation by Vinca alkaloids. Cancer Res. 1991; 51: 2212-2212.
12. Dhamodharan RI, Jordan MA, Thrower D, Wilson L, Wadsworth P. Vinblastine suppresses dynamics of individual microtubules in living cells. Mol Biol Cell 1995; 6: 1215-1229. http://cancerres.aacrjournals.org/cgi/ijlink?linkType=ABST&journalCode=molbiolcell&resid=6/9/1215.
13. Jordan MA, Himes RH, Wilson L. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res 1985; 45: 2741-2747
14. Budman DR. Vinorelbine (Navelbine): A third-generation vinca alkaloid. Cancer Invest 1997; 15: 475-490.
15. Kruczynski A, Barret JM., Etievant C, Colpaert F, Fahy J, Hill BT. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem Pharmacol 1998; 55: 635-648.
16. Binet S, Chaineau E, Fellous A, et al. Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules. Int J Cancer 1990; 46: 262-266.
17. Ashizawa T, Miyoshi K, Asada M, et al. Anti-tumour activity of navelbine, a new vinca-alkaloid analog. Gan To Kagaku Ryoho 1993; 20: 59-66.
18. Jordan MA, Thrower D, Wilson L. Mechanism of Inhibition of Cell Proliferation by Vinca Alkaloids. Cancer Res 1991; 51: 2212-2222.
19. Cleveland D W, Lopata MA, Sherline P, Kirschner MW. Unpolymerized tubulin modulates the level of tubulin mRNAs. Cell 1981; 25: 537-546.
20. Palmer, CG, Livengood D, Warren AK, Simpson P J, Johnson IS. The action of vincaleukoblastine on mitosis in vitro. Exp Cell Res 1960; 20: 198-202.
21. Madoc-Jones H, Mauro F. Interphase action of vinblastine and vincristine: differences in their lethal action through the mitotic cycle of cultured mammalian cells. J Cell Physiol 1968; 72: 185-196.
22. Taylor EW. The mechanism of colchicine inhibition of mitosis. J Cell Biol 1965; 25: 145-60.
23. Zieve GW, Turnbull, D„Mullins JM, Mclntosh, JR. Production of large numbers of mammalian mitotic cells by use of the reversible microtubule inhibitor nocodazole. Exp Cell Res 1980; 126: 397-405.
24. Ngan VK, Bellman K, Hill BT, Wilson L, Jordan MA, Mechanism of Mitotic Block and Inhibition of Cell Proliferation by the Semisynthetic Vinca Alkaloids Vinorelbine and Its Newer Derivative Vinflunine. Mol Pharmacol 2001; 60: 225-232.
25. Hays TS, Salmon ED. Poleward force at the kinetochore in metaphase depends on the number of kinetochore microtubules. J Cell Biol 1990; 110: 391-404
26. Nicklas RB, Ward SC, Gorbsky GJ. Kinetochore chemistry is sensitive to tension and may link mitotic forces to a cell cycle checkpoint. J Cell Biology 1995; 130: 929-939.
27. Mitchison TJ. Poleward microtubule flux in the mitotic spindle; evidence from photoactivation of fluorescence. J Cell Biol 1989; 109: 637-652.
28. Waters JC, Mitchison TJ, Rieder CL, Salmon ED. The kinetochore microtubule minus-end disassembly associated with poleward flux produces a force that can do work. Mol Biol Cell 1996; 7: 1547-1558.
29. Kruczynski A, Barret JM, Etievant C, Colpaert F, Fahy J, Hill BT. Antimitotic and tubulin interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochemical Pharmacol 1998; 55: 635-648.
30. Lobert S, Ingram J, Hill B, Correia J. A comparison of thermodynamic parameters for vinorelbine-and vinflunine-induced tubulin self-association by sedimentation velocity. Mol Pharmacol 1998; 53: 908-915.
31. Sutapa S, Ying C, Shamit D, Enfeng W, Debabrata M. VEGF Neutralizing Antibody Increases The Therapeutic Efficacy Of Vinorelbine For Renal Cell Carcinoma. J Cell Mol Med 2010; 14(3): 647-658.
32. Bonfil RD, Russo DM, Schmilovich AJ. Exposure to vinorelbine inhibits in vitro proliferation and invasiveness of transitional cell bladder carcinoma. J Urol 1996; 156(2): 517-521.
33. Escuin D, Kline ER, Giannakakou P. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor- 1alpha accumulation and activity by disrupting microtubule function. Cancer Res 2005; 65(19): 9021-9028
34. Gasparini G, Caffo O, Barni S, et al. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol 1994; 12: 2094-2101.
35. De Maio E, Pacilio C, Gravina A, et al. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial. BMC Cancer 2007; 7: 50-57.
36. Romero Acuña L, Langhi M, Pérez J, et al. Vinorelbine and Paclitaxel as First-Line Chemotherapy in Metastatic Breast Cancer. J Clin Oncol 1999; 17 (1): 74-81.
37. Toi M, Saeki T, Aogi K, et al. Late Phase II Clinical Study of Vinorelbine Monotherapy in Advanced or Recurrent Breast Cancer Previously Treated with Anthracyclines and Taxanes. J Clin Oncol 2005; 35 (6): 310-315.
38. Freyer G, Delozier T, Lichinister M., et al. Phase II Study of Oral Vinorelbine in First-Line Advanced Breast Cancer Chemotherapy. J Clin Oncol 2003; 21 (1): 35-40.
39. Mustacchi G, Muggia M, Milani S, Ceccherini R, Leita ML, Dellach C. A phase II study of cisplatin and vinorelbine in patients with metastatic breast cancer. Ann Oncol 2002; 1: 1730-1736
40. Kornek GV, Ulrich-Pur H, Penz M, et al. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. J Clin Oncol 2001; 1: 621-627.
41. Stathopoulos GP, Rigatos SK, Pergantas N, et al. Phase ii trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer. J Clin Oncol 2002; 1: 37-41.
42. Heinemann V, Di Gioia D, Vehling-Kaiser U, et al. A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer. Ann Oncol 2011; 1: 603-608
43. Fazeny B, Zifko U, Meryn S, Huber H, Grisold W, Dittrich C. Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel - a phase II study. Cancer Chemother Pharmacol 1996; 39(1-2): 150-156.